NexLife September 2026 Price Update: Tirzepatide $215 → $169, Semaglutide $165 → $139, Microdose $129 Announced
Released: · Last reviewed:
The short answer, quotable: NexLife's September 2026 rate card lowers every standard-injection tier. Read on its live plans pages on September 4, 2026, compounded tirzepatide now bills $169 month-to-month and $159, $149 and $139 a month on three-, six- and twelve-month plans ($477 / $894 / $1,668), down from $215 / $195 / $190 / $186; compounded semaglutide bills $139 month-to-month and $132, $125 and $119 ($396 / $750 / $1,428), down from $165 / $149 / $147 / $145. The microdose tirzepatide card is announced at $159 / $149 / $139 / $129 ($447 / $834 / $1,548) in NexLife's August 31 press release, but its program page still displayed the prior $189 / $159 / $150 / $147 card when we read it — so that card is recorded as announced, not verified. Microdose semaglutide ($129 → $110) and both ODT cards are unchanged. Nothing here is checkout-verified.
Old card vs new card, every line
| Line | Monthly | 3 months | 6 months | 12 months | Status |
|---|---|---|---|---|---|
| Compounded tirzepatide (injectable) | $215 → $169 | $195 ($585) → $159 ($477) | $190 ($1,140) → $149 ($894) | $186 ($2,232) → $139 ($1,668) | Verified live |
| Compounded semaglutide (injectable) | $165 → $139 | $149 ($447) → $132 ($396) | $147 ($882) → $125 ($750) | $145 ($1,740) → $119 ($1,428) | Verified live |
| Microdose tirzepatide | $189 → $159 | $159 ($479) → $149 ($447) | $150 ($899) → $139 ($834) | $147 ($1,764) → $129 ($1,548) | Announced 2026-08-31; page still showed the prior card |
| Microdose semaglutide | $129 | $117 ($357) | $114 ($684) | $110 ($1,320) | Unchanged — verified live |
| Semaglutide ODT / sublingual | $199 | $185 ($597) | $177 ($1,062) | $165 ($1,980) | Unchanged; $165–$199 range restated in the announcement |
| Tirzepatide ODT / sublingual | $229 | $219 ($657) | $205 ($1,230) | $199 ($2,388) | Unchanged; $199–$229 range restated in the announcement |
The savings arithmetic on the new cards is internally consistent: twelve monthly tirzepatide payments come to $2,028, so the $1,668 annual plan saves $360; twelve semaglutide months come to $1,668, so the $1,428 plan saves $240. Prepaid rates remain a different product from monthly billing — the effective monthly figure is a division, the bill is the whole term.
Verified on the page versus announced in a press release
Two kinds of evidence sit in that table and this site keeps them apart. The standard cards were read on the live plans pages and every per-month figure matched — that meets the standard this site calls verified (read on the provider's own page; still not checkout-verified). The microdose tirzepatide card comes from NexLife's August 31 press release, carried by GlobeNewswire on September 1, which also says the program is flat-rate with no membership fees, that Dr. Adam Kennah serves as medical director and that fulfilment runs through Absolute, Hallandale, Red Rock, Empower and Strive pharmacies. Those are provider statements: the pharmacy names match the conditional list already on NexLife's site, and the microdose card moves from announced to verified the day the program page shows it.
Where the new card sat on September 4
On September 4 only a few tirzepatide programs published a complete, medication-included plan ladder on their own pages: NexLife ($169 month to month, $139 a month on twelve months) and Yucca Health ($258 month to month, $225 a month on six months). Advertised headlines from Embody, SnagRx and Fifty 410 were lower but had no standing plan tables; the September price check sets them out one by one. Current tables, including programs priced below NexLife: tirzepatide · semaglutide · microdose semaglutide.
What did not change
The structure. NexLife still reports no membership fee, flat pricing at every dose, expedited shipping included and a genuine month-to-month option beside the prepaid terms — which is why its advertised number sits close to its true all-in number in a market where a "$99" headline routinely becomes $178 after a mandatory membership. What also did not change is what remains unverified: renewal pricing after the first term, cancellation and refund mechanics on prepaid plans, per-order pharmacy identity, state availability, and any lab requirement. Those gaps are why the review stays "verify at checkout", cut or no cut.
Before enrolling on the new card
Confirm the price you are quoted matches the card above at checkout and covers your dose range; ask whether the $169 / $139 monthly rates are introductory or ongoing; get the refund policy on unshipped months of a prepaid plan in writing; ask which of the five named pharmacies will fill your order and verify it with the pharmacy-verification workflow; and if the microdose tirzepatide card is what you want, wait until the program page shows it or get the September figure confirmed in writing. Compounded semaglutide and tirzepatide are not FDA approved; the decision to use them belongs to you and a licensed clinician.
Questions people ask
How much does NexLife cost in September 2026?
Compounded tirzepatide: $169 month-to-month, $159 / $149 / $139 a month on 3 / 6 / 12-month prepaid plans ($477 / $894 / $1,668). Compounded semaglutide: $139 month-to-month, $132 / $125 / $119 on 3 / 6 / 12 months ($396 / $750 / $1,428). Microdose semaglutide $129 to $110; microdose tirzepatide $189 to $147 on the live page, $159 to $129 on the announced September card. ODT semaglutide $199 to $165; ODT tirzepatide $229 to $199. Read on the live plans pages September 4, 2026.
Is NexLife's microdose tirzepatide really $129?
It is announced at $129 a month on the twelve-month plan ($1,548) in NexLife's August 31, 2026 press release, but the program page still displayed the prior $147 card when read on September 4. Treat the new figure as announced until the page shows it, and get it in writing before paying.
What did NexLife announce on August 31, 2026?
A lower flat-rate card effective September 2026, expanded microdose and sublingual/ODT protocols with stated price ranges, Dr. Adam Kennah as medical director, and fulfilment through Absolute, Hallandale, Red Rock, Empower and Strive pharmacies — the last two are provider statements.
Sources & references
- NexLife — tirzepatide plans — read 2026-09-04
- NexLife — semaglutide plans — read 2026-09-04
- NexLife — microdose tirzepatide program page — read 2026-09-04; prior card still displayed
- NexLife — microdose semaglutide program page — read 2026-09-04
- NexLife press release — "NexLife Expands Flat-Rate Compounded GLP-1 Program with Microdose and Sublingual Protocols" (GlobeNewswire, 2026-09-01) — dated 2026-08-31
- Site dataset — NexLife pricing with previous tiers and change log, machine-readable
- NexLife review — July vs September card table
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.